PB8 Stock Chart & Stats
€29.60
€0.40(1.37%)
At close: 4:00 PM EDT
€29.60
€0.40(1.37%)
Day’s Range― - ―
52-Week Range€24.20 - €50.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€1.26B
Enterprise Value€1.99K
Total Cash (Recent Filing)€81.99M
Total Debt (Recent Filing)€788.77M
Price to Earnings (P/E)14.8
Beta0.72
Next Earnings
Nov 11, 2026EPS Estimate
0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.46
Shares Outstanding21,068,682
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)3.31
Price to Sales (P/S)0.84
P/FCF Ratio129.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€49.75Price Target Upside68.08% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)2.85
Revenue Forecast (FY)€1.33B
Bulls Say, Bears Say
Bulls Say
Acquisition-driven GrowthRecent product portfolio acquisitions are driving stronger sales and measurable market share gains, supporting revenue expansion across core markets.
Margin Expansion From Product MixFavorable product mix and operating leverage in the Animal Health business have lifted gross and operating margins, improving profitability per unit of sales.
Raised Guidance And Demand For Medicated Feed AdditivesManagement's raised full-year guidance reflects confidence as stronger-than-expected demand for medicated feed additives and opportunities in international markets support additional sales momentum.
Bears Say
Financial And Governance UncertaintyElevated leverage and an ongoing CEO transition increase uncertainty around execution and the company’s capital structure, potentially constraining strategic flexibility.
Margin Pressure From Tariffs And Higher CostsTariff-related inventory costs combined with planned increases in selling and administrative spending are likely to cause modest margin deterioration and compress operating results.
Relative Profitability And Growth LagAnalyst maintains an underperform rating citing lower profitability and slower revenue growth compared with industry peers, which could limit relative shareholder returns.
Phibro Animal Health News
PB8 FAQ
What was Phibro Animal Health’s price range in the past 12 months?
Phibro Animal Health lowest stock price was €24.20 and its highest was €50.00 in the past 12 months.
What is Phibro Animal Health’s market cap?
Phibro Animal Health’s market cap is €1.26B.
When is Phibro Animal Health’s upcoming earnings report date?
Phibro Animal Health’s upcoming earnings report date is Nov 11, 2026 which is in 75 days.
How were Phibro Animal Health’s earnings last quarter?
Phibro Animal Health released its earnings results on Aug 26, 2026. The company reported €0.73 earnings per share for the quarter, beating the consensus estimate of €0.612 by €0.118.
Is Phibro Animal Health overvalued?
According to Wall Street analysts Phibro Animal Health’s price is currently Undervalued.
Does Phibro Animal Health pay dividends?
Phibro Animal Health does not currently pay dividends.
What is Phibro Animal Health’s EPS estimate?
Phibro Animal Health’s EPS estimate is 0.66.
How many shares outstanding does Phibro Animal Health have?
Phibro Animal Health has 21,068,682 shares outstanding.
What happened to Phibro Animal Health’s price movement after its last earnings report?
Phibro Animal Health reported an EPS of €0.73 in its last earnings report, beating expectations of €0.612. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Phibro Animal Health?
Currently, no hedge funds are holding shares in DE:PB8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Phibro Animal Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€49.75 (68.08% Upside)
€49.75 (68.08% Upside)
Blogger Sentiment
Bullish
DE:PB8 Sentiment 60%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
22.28%
12-Months-Change
Fundamentals
Return on Equity
1.20%
Trailing 12-Months
Asset Growth
9.71%
Trailing 12-Months
Company Description
Phibro Animal Health
Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro develops, manufactures, and markets products tailored for various food-producing animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its Animal Health offerings encompass a broad range of pharmaceutical and biological products. These include antimicrobials (both chemical and biological agents) designed to prevent and treat bacterial ailments; anticoccidials, primarily used to control and prevent coccidiosis in poultry and cattle; anthelmintics for combating parasitic intestinal worm infestations; and specific anti-bloat treatments for cattle grazing on legume or wheat pastures. Additionally, the company provides specialized nutritional supplements engineered to enhance animal health and performance, alongside vaccines predominantly for the poultry and swine industries to protect against diseases. The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates, featuring elements such as zinc, manganese, copper, iron, and other vital compounds. Furthermore, under its Performance Products segment, Phibro supplies an assortment of specialty ingredients that find application in diverse industries, including personal care, industrial chemicals, and chemical catalysts. Phibro's animal health and mineral nutrition products reach customers through a multi-channel distribution network, including its own local sales offices, direct sales to integrated poultry, swine, and cattle operations, and through commercial animal feed producers, wholesalers, and distributors. The company boasts an extensive international presence, conducting business across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific region. Initially known as Philipp Brothers Chemicals, Inc., the company adopted the name Phibro Animal Health Corporation in July 2003. It was officially incorporated in 2014 and maintains its corporate headquarters in Teaneck, New Jersey.
PB8 Company Deck
PB8 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong operating momentum and record full-year results—double-digit revenue growth, a 39% increase in adjusted EBITDA, successful integration of the MFA acquisition, and tangible benefits from the Phibro Forward program. Management provided conservative but constructive FY2027 guidance while reserving downside for specific risks (notably the regulatory status of virginiamycin in Brazil). Cash generation was constrained in FY2026 by a large inventory build and CapEx requirements, and near-term impacts include a planned plant closure with one-time costs and a weak Performance Products segment. Overall, the positive operating performance, sizable EBITDA gains, and strategic integration successes outweigh the manageable near-term headwinds and uncertainties.View all DE:PB8 earnings summariesPB8 Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€49.75
▲(68.08% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month









